Autologous Tcm Cells Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC)

Last updated: December 16, 2018
Sponsor: Beijing Friendship Hospital
Overall Status: Active - Recruiting

Phase

2

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT03432156
BeijingFH-JW-180202-1
  • Ages 18-80
  • All Genders

Study Summary

Autologous Tcm cells immunotherapy combining surgery or chemotherapy could effectively prolong survival period and improve quality of life in patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Be willing and able to provide written informed consent for the study.

  2. Subjects with pathologically confirmed stage II NSCLC.

  3. Subjects with stage II NSCLC had treatment with surgical resection and 4 cycles ofpostoperative adjuvant chemotherapy before the study.

  4. Karnofsky (KPS) ≥ 60.

  5. One or more Serum tumor markers such as carcinoembryonic antigen (CEA), CA125,cytokeratin-19 fragment (CYFRA21-1), neuron-specific enolase (NSE), pro-grp andangiopoietin-2 (Ang-2) are double higher than normal level or durative elevator onthree consecutive tests.

  6. Adequate hematologic and end-organ function.

  7. Subjects who could receive treatment with at least 3 cycles of autologous Tcm cellsimmunotherapy.

  8. Subjects must be received auxiliary examination and record these results in detailbefore and after immunotherapy.

  9. Subjects must meet the indications for autologous Tcm cells immunotherapy.

Exclusion

Exclusion Criteria:

  1. Subjects with lung nodules, lymph nodes, brain, liver, bone or adrenal metastasisbefore the study.

  2. Subjects who are using immunosuppressive agents or long-term immunosuppressive agentsafter organ transplantation.

  3. Subjects with severe abnormality of coagulation.

  4. History or any evidence of hemorrhage.

  5. Subjects with severe infection or high fever.

  6. Subjects with severe autoimmune diseases.

  7. Subjects with persistent or intractable epilepsy.

  8. Subjects with merging other malignant neoplasms.

  9. Subjects with mental disorder.

  10. Subjects with heart, liver or kidney diseases.

  11. Major surgeries except for surgical resection of NSCLC were performed in 4 weeksbefore the study.

  12. Autologous bone marrow transplantation (ABMT) in 4 weeks before the study.

  13. Concurrent treatment or treatment on another study in 4 weeks before the study.

  14. Pregnancy or breast-feeding.

  15. There are drug abuse, medical treatment, mental illness and social disorders thatwould interfere with subjects' participation, or confound the results of the trial.

  16. Any condition that would interfere with or endanger the safety and compliance ofsubjects.

Study Design

Total Participants: 68
Study Start date:
April 03, 2018
Estimated Completion Date:
December 31, 2020

Study Description

Autologous central memory T cells (Tcm) cells immunotherapy is to collect patient's own immune cells in peripheral blood and then given back to the patient after amplified in vitro that can improve the anti-tumor immune response and is effective treatment of the cancer. Tcm cells are effective anti-tumor immune cells that exhibit the long-term survival and self-renewal capacity in vivo. Autologous Tcm cells immunotherapy combining surgery or chemotherapy could effectively prolong survival period and improve quality of life in patients.

Lung cancer is the leading cause of cancer related deaths, which account for one third of all deaths due to cancer worldwide. The most common histologic type of lung cancer is non-small-cell lung cancer (NSCLC) that is accounting for almost 85%. There are no targeted therapeutics in patients with high-risk recurrent stage II NSCLC after postoperative chemotherapy, therefore, autologous Tcm cells immunotherapy would be a safe and effective treatment.

The aim of this study is to assess the efficacy and safety of autologous Tcm cells immunotherapy in patients with high-risk recurrent stage II NSCLC after postoperative chemotherapy. Patients will be randomized 1:1 either to the experimental arm to receive 3 cycles of autologous Tcm cells immunotherapy or to the no intervention arm.

Connect with a study center

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing 100050
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.